Terms: = Lung cancer AND PML, TRIM19, 5371, ENSG00000140464, MYL, PP8675, RNF71 AND Prognosis
11 results:
1. Interrogating the precancerous evolution of pathway dysfunction in lung squamous cell carcinoma using XTABLE.
Roberts M; Ogden J; Hossain ASM; Chaturvedi A; Kerr ARW; Dive C; Beane JE; Lopez-Garcia C
Elife; 2023 Mar; 12():. PubMed ID: 36892933
[TBL] [Abstract] [Full Text] [Related]
2. Identification of a prognostic immune-related signature for small cell lung cancer.
Xie Q; Chu H; Yi J; Yu H; Gu T; Guan Y; Liu X; Liang J; Li Y; Wang J
Cancer Med; 2021 Dec; 10(24):9115-9128. PubMed ID: 34741430
[TBL] [Abstract] [Full Text] [Related]
3. Probable progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome with immunosuppressant dose reduction following lung transplantation: a case report and literature review.
Ishii K; Yamamoto F; Homma S; Okada Y; Nakamichi K; Saijo M; Tamaoka A
BMC Neurol; 2019 Oct; 19(1):263. PubMed ID: 31672142
[TBL] [Abstract] [Full Text] [Related]
4. Inhibition of protein kinase CK2 sensitizes non-small cell lung cancer cells to cisplatin via upregulation of pml.
Yang B; Yao J; Li B; Shao G; Cui Y
Mol Cell Biochem; 2017 Dec; 436(1-2):87-97. PubMed ID: 28744813
[TBL] [Abstract] [Full Text] [Related]
5. Ubiquitination of tumor suppressor pml regulates prometastatic and immunosuppressive tumor microenvironment.
Wang YT; Chen J; Chang CW; Jen J; Huang TY; Chen CM; Shen R; Liang SY; Cheng IC; Yang SC; Lai WW; Cheng KH; Hsieh TS; Lai MZ; Cheng HC; Wang YC; Chen RH
J Clin Invest; 2017 Aug; 127(8):2982-2997. PubMed ID: 28691927
[TBL] [Abstract] [Full Text] [Related]
6. Pulmonary middle lobectomy for non-small-cell lung cancer: effectiveness and prognostic implications.
Mazza F; Ferrari E; Maineri P; Venturino M; Dozin B; Ratto GB
Eur J Cardiothorac Surg; 2015 Dec; 48(6):e117-23. PubMed ID: 26374866
[TBL] [Abstract] [Full Text] [Related]
7. Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes.
Heaphy CM; Subhawong AP; Hong SM; Goggins MG; Montgomery EA; Gabrielson E; Netto GJ; Epstein JI; Lotan TL; Westra WH; Shih IeM; Iacobuzio-Donahue CA; Maitra A; Li QK; Eberhart CG; Taube JM; Rakheja D; Kurman RJ; Wu TC; Roden RB; Argani P; De Marzo AM; Terracciano L; Torbenson M; Meeker AK
Am J Pathol; 2011 Oct; 179(4):1608-15. PubMed ID: 21888887
[TBL] [Abstract] [Full Text] [Related]
8. Prospective study into the incidence of Lambert Eaton myasthenic syndrome in small cell lung cancer.
Payne M; Bradbury P; Lang B; Vincent A; Han C; Newsom-Davis J; Talbot D
J Thorac Oncol; 2010 Jan; 5(1):34-8. PubMed ID: 19934775
[TBL] [Abstract] [Full Text] [Related]
9. [Expression of promyelocytic leukaemia protein in lung carcinomas and clinical significance thereof].
Zhao ZL; Huang QY; Xu S; Zhang L; Zhao HR
Zhonghua Yi Xue Za Zhi; 2006 Dec; 86(47):3362-6. PubMed ID: 17313836
[TBL] [Abstract] [Full Text] [Related]
10. [Long-term prognosis after surgery for pathological stage III lung cancer].
Togashi K; Saito M; Shinohara H; Wakabayashi T; Asami F
Kyobu Geka; 2005 Oct; 58(11):938-41; discussion 942-3. PubMed ID: 16235839
[TBL] [Abstract] [Full Text] [Related]
11. Circulating tumour-derived DNA and RNA markers in blood: a tool for early detection, diagnostics, and follow-up?
Bremnes RM; Sirera R; Camps C
Lung Cancer; 2005 Jul; 49(1):1-12. PubMed ID: 15949585
[TBL] [Abstract] [Full Text] [Related]
